BNTC - Benitec Biopharma Ltd ADR

BNTC - Benitec Biopharma Ltd ADR

https://benitec.com

Strong Sell Momentum: Bearish

Recent News

Powered by Alpha Vantage

Is McKesson ( MCK ) Stock Outpacing Its Medical Peers This Year?

Zacks Commentary • 2 months, 3 weeks ago • score: 0.01

Here is how McKesson (MCK) and Benitec Biopharma Limited (BNTC) have performed compared to their sector so far this year.

Is Benitec Biopharma ( BNTC ) Outperforming Other Medical Stocks This Year?

Zacks Commentary • 3 months, 1 week ago • score: 0.11

Here is how Benitec Biopharma Limited (BNTC) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Benitec Biopharma ( BNTC ) This Year?

Zacks Commentary • 3 months, 3 weeks ago • score: 0.31

Here is how Benitec Biopharma Limited (BNTC) and Concentra Group (CON) have performed compared to their sector so far this year.

Is Benitec Biopharma ( BNTC ) Stock Outpacing Its Medical Peers This Year?

Zacks Commentary • 4 months, 1 week ago • score: 0.19

Here is how Benitec Biopharma Limited (BNTC) and Concentra Group (CON) have performed compared to their sector so far this year.

What Makes Benitec Biopharma ( BNTC ) a New Buy Stock

Zacks Commentary • 4 months, 3 weeks ago • score: 0.28

Benitec Biopharma (BNTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Are Medical Stocks Lagging Ascendis Pharma ( ASND ) This Year?

Zacks Commentary • 4 months, 4 weeks ago • score: 0.08

Here is how Ascendis Pharma A/S (ASND) and Benitec Biopharma Limited (BNTC) have performed compared to their sector so far this year.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Benitec Biopharma Inc., a developing biotechnology company, is focused on the development of new genetic drugs. The company is headquartered in Hayward, California.

52W High

$17.15

52W Low

$8.06

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

0.43

Valuation

As of 2025-03-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.27

EV/Revenue (<3 favorable)

10457.68

P/S (TTM) (<3 favorable)

2770.13

P/B (<3 favorable)

3.74

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

3.12%

Institutions (25–75% balanced)

90.69%

Shares Outstanding

26,250,500

Float

12,567,100

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-03-31 (Overview)

Revenue (TTM)

7,000

Gross Profit (TTM)

0

EPS (TTM)

-5.03

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.49%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.13

Momentum

Bearish momentum

Value

0.4802

Previous

0.4691

Trend

Rising

Signal Cross

No cross

As of

Sep. 11, 2025